摘要
配位化学为设计新型和治疗剂包括金属药物提供了很大的空间。金属络合物广泛用作有效药物,例如癌症治疗剂,抗炎剂,抗糖尿病药物或抗微生物剂和诊断剂,证明了金属离子的细胞毒性可以通过适当选择配体来精确控制。放射性同位素的成功靶向依赖于配体设计和金属氧化状态。铂,钌,钴,铜和其他d-嵌段金属离子的配合物已经在医学中使用了很长一段时间,但是只有在理解其作用机制的分子基础方面取得了近期的进展。由于上述目的,我们决定准备详细描述基于靶向的研究,针对设计和应用的可能性,以广义的治疗定义中已知的金属离子络合物作用机制。该评论还涵盖了上述方法的进展,局限性和挑战,并强调了医药和制药领域众所周知的新型金属药物的优势。
关键词: 金属药物,配位化合物,癌症治疗药物,抗菌药物,医学诊断,活动机制
Current Medicinal Chemistry
Title:Metallopharmaceuticals in Therapy - A New Horizon for Scientific Research
Volume: 25 Issue: 15
关键词: 金属药物,配位化合物,癌症治疗药物,抗菌药物,医学诊断,活动机制
摘要: Coordination chemistry offers much scope for the design of novel and therapeutic agents, including metallopharmaceuticals. The widespread use of metal complexes as effective pharmaceuticals, e.g. cancer therapeutic, anti-inflammatory, antidiabetic drugs or antimicrobial and diagnostic agents, demonstrates that the cytotoxicity of metal ions can be finely controlled via the appropriate choice of ligands. The successful targeting of radioisotopes again depends on the ligand design and metal oxidation state. The complexes of platinum, ruthenium, cobalt, copper and other d-block metal ions have been used in medicine for a long time but only recent advances have been made in understanding the molecular basis of mechanism of their action. Due to the above mentioned purpose, we decided to prepare a detailed description of target-based research, directed towards a design and application possibilities, with the known mechanisms of action of metal ion complexes in the broad sense of therapy definition. The review also covers the progress, limitations and challenges of the above-mentioned approaches and emphasizes the advantages of well known and new metallopharmaceuticals in medicine and pharmacy.
Export Options
About this article
Cite this article as:
Metallopharmaceuticals in Therapy - A New Horizon for Scientific Research, Current Medicinal Chemistry 2018; 25 (15) . https://dx.doi.org/10.2174/0929867325666171206102501
DOI https://dx.doi.org/10.2174/0929867325666171206102501 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety and Efficacy of Mavrilimumab For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Current Rheumatology Reviews 2(3)-Aryl-thio(oxy)-methylquinoxaline Derivatives: A New Class of P-Glycoprotein-Mediated Drug Efflux Inhibitors
Medicinal Chemistry COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Toxicity Burden in Head and Neck Cancer: Past, Present, and Future Strategies
Current Cancer Therapy Reviews Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Current Cancer Drug Targets Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Experimental Onco-Immunology Revisited
Current Cancer Therapy Reviews Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Role of FoxM1 in the Progression and Epithelial to Mesenchymal Transition of Gastrointestinal Cancer
Recent Patents on Anti-Cancer Drug Discovery Recent Concise Viewpoints of Chronic Active Epstein-Barr Virus Infection
Current Pediatric Reviews The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents NIPAM/PEG/ MoS2 Nanosheets for Dual Triggered Doxorubicin Release and Combined Chemo-photothermal Cancer Therapy
Current Drug Delivery In Vivo Application and Tracking of Baculovirus
Current Gene Therapy Application of Proteome Analysis to the Assessment of Prognosis and Response Prediction in Clinical Oncology
Current Cancer Drug Targets Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Can Chest Computed Tomography Findings of Symptomatic COVID-19 Patients Upon Admission Indicate Disease Prognosis and Clinical Outcome?
Current Medical Imaging Tumor Initiating Cells
Current Pharmaceutical Biotechnology